SELLAS Life Sciences (SLS) Liabilities and Shareholders Equity (2019 - 2024)
Historic Liabilities and Shareholders Equity for SELLAS Life Sciences (SLS) over the last 9 years, with Q3 2024 value amounting to $26.5 million.
- SELLAS Life Sciences' Liabilities and Shareholders Equity rose 22778.88% to $26.5 million in Q3 2024 from the same period last year, while for Sep 2024 it was $72.3 million, marking a year-over-year decrease of 576.54%. This contributed to the annual value of $6.2 million for FY2023, which is 7030.51% down from last year.
- Per SELLAS Life Sciences' latest filing, its Liabilities and Shareholders Equity stood at $26.5 million for Q3 2024, which was up 22778.88% from $15.1 million recorded in Q2 2024.
- In the past 5 years, SELLAS Life Sciences' Liabilities and Shareholders Equity registered a high of $46.0 million during Q4 2020, and its lowest value of $6.2 million during Q4 2023.
- Its 5-year average for Liabilities and Shareholders Equity is $24.9 million, with a median of $24.4 million in 2024.
- Per our database at Business Quant, SELLAS Life Sciences' Liabilities and Shareholders Equity crashed by 7030.51% in 2023 and then surged by 22778.88% in 2024.
- SELLAS Life Sciences' Liabilities and Shareholders Equity (Quarter) stood at $46.0 million in 2020, then crashed by 42.94% to $26.3 million in 2021, then decreased by 20.29% to $20.9 million in 2022, then crashed by 70.31% to $6.2 million in 2023, then skyrocketed by 326.19% to $26.5 million in 2024.
- Its Liabilities and Shareholders Equity stands at $26.5 million for Q3 2024, versus $15.1 million for Q2 2024 and $24.4 million for Q1 2024.